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Abstract: The aim of the present study was to evaluate the protective activity of aqueous extract from Platycodon gran-
diflorum (BC703) on thioacetamide (TA)-induced hepatotoxicity in mice. We found that BC703 significantly decreased 
mortality and the change in serum transaminase following TA administration. The group treated with BC703 at doses 
of 1, 5, and 10 mg/kg produced significant hepatoprotective effects against TA-induced liver damage by decreasing the 
activities of serum enzymes, nitric oxide and lipid peroxidation in dose-dependent manners. Histopathological studies 
further substantiated the protective effect of BC703. These results show the hepatoprotective activity of aqueous extract 
from Platycodon grandiflorum on thioacetamide-induced fulminant hepatic failure. (DOI: 10.1293/tox.24.223; J Toxicol 
Pathol 2011; 24: 223–228)
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Introduction
The roots of Platycodon grandiflorum have been con-
sumed as a foodstuff and as a folk remedy for diseases such 
as bronchitis, asthma, pulmonary tuberculosis and inflam-
mation1. It was reported to contain a lot of carbohydrates (at 
least 90%), protein (2.4%), lipids (0.1%) and ash (1.5%)1,2. 
Polysaccharides obtained from many natural sources repre-
sent a structurally diverse class of macromolecules, and are 
known to affect a variety of biological responses. It has been 
reported that the polysaccharides isolated from the root of 
Platycodon  grandiflorum prevent obesity, hypecholester-
olemia, hypertension, diabetes and hyperlipidemia2,3. The 
inulin-type  polysaccharides,  (1→2)-β-D-fructan,  isolated 
from the roots of Platycodon grandiflorum demonstrated 
the selective immune-modulating effects on B cells and 
macrophages4. Triterpenoid saponins, such as platycodins 
(A, D, D2, and D3), 2 and 3-O-acetyl polygalacin D2, platy-
conic acid and platycosides (A, B, C, D, E, and F), were also 
found int eh roots of the Platycodon grandiflorum4. These 
saponins are believed to have a wide range of health benefits 
and to prevent chemicals-induced hepatotoxicity5,6.
Rodent models of toxin-induced hepatotoxicity are 
used to elucidate the biochemical processes involved in 
many forms of liver disease and to evaluate the potential 
candidates for hepatoprotectants7. An animal model of ful-
minant hepatic failure induced by the thioacetamide (TA) 
has been described previously7,8. The animal model for 
TA-induced fulminant hepatic failure was characterized by 
severe liver function impairment, massive hepatocyte ne-
crosis and apoptosis9. Within a short period of administra-
tion, TA is converted to thioacetamide sulfoxide (TASO) by 
the oxidase system. It is further metabolized by cytochrome 
P450 monooxygenases to thioacetamide sulfone (TASO2), a 
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highly reactive electrophilic metabolite10,11. Covalent bind-
ing of this polar product to cellular macromolecules exerts 
hepatotoxicity, leading to generation of reactive oxygen spe-
cies (ROS)10–12.
In the present study, we aimed to investigate the hepa-
toprotective effect of the standardized Platycodon grandil-




Assay kits for thiobarbituric acid reactive substances 
(TBARS), glutathione (GSH), nitric oxide (NO) were pur-
chased from BioAssay Systems (Hayward, CA, USA). Test 
kits for serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), blood urea nitrate (BUN), creati-
nine (CRE) were obtained from IDEXX (Westbrook, ME, 
USA). TA and other chemicals were obtained from Sigma 
chemicals (St. Louis, MO, USA). HPLC-grade acetoni-
trile and methanol were obtained from Mallinckrodt Baker 
(Phillipsburg, NJ, USA).
Preparation of standardized Platycodon grandiflorum 
aqueous extract
The standardized Platycodon  grandiflorum aque-
ous extract (BC703) was manufactured by SkyHerb Phar-
maceuticals (Zhejiang, China) in accordance with good 
manufacturing practices (GMP). Briefly, the dried roots of 
Platycodon grandiflorum (100 g) were cut into slices and 
extracted in distilled water with occasional shaking at 60–
90 °C for 6–10 hours. The aqueous extract was then filtered, 
concentrated under reduced pressure in a rotary evaporator 
and spray-dried into powder (36 g). It has previously been 
reported that the aqueous extracts of the roots of Platycodon 
grandiflorum contain an inulin-type polyfructose, (1→2)-
β-D-  fructan2,3,13. It also includes deapio-platycoside E, 
platycoside E, deapio-platycodin D3, platycodin D3, deap-
io-platycodin D, platycodin D, polygalacin D, 3″-O-acetyl 
polygalacin D, platycodin A and 2″-O-acetyl polygalacin D. 
Therefore, BC703 was standardized in reference to platyco-
din D (at least 0.8%) using a validated HPLC assay method 
as previously described with some modifications14.
Animals and treatments
Male ICR mice, weighing between 32 and 36 g at the 
age of 5–6 weeks, were used for this study. They were ob-
tained from Orient Bio (Sungnam, Korea) and acclimated 
for one week before experiments. Healthy ICR mice were 
randomly allocated into 5 groups of 6 male mice each. The 
mice in the negative and positive control groups were orally 
given distilled water. The others were orally administered 
with BC703 (1, 5 and 10 mg/kg) for three consecutive days. 
At 3 h after the last oral administration, mice were intraper-
itoneally injected with saline or 200 mg/kg of TA. Twenty-
four hours after TA administration, the surviving mice were 
killed by cardiac puncture after being anesthetized lightly 
with carbon dioxide. The dead animals were necropsied as 
soon as they were found and excluded from the histopatho-
logical and biochemical examination. Collected blood sam-
ples were separated by centrifugation at 800 g for 15 min, 
and the serum samples were subjected to biochemical inves-
tigations. Liver samples from each mouse were removed for 
histopathological and biochemical examination. The experi-
mental protocols were approved by the Institutional Animal 
Care and Use Committee of Chungnam National University 
(Deajeon, Korea).
Serum biochemical examination
The serum ALT, AST, BUN and CRE activities were 
determined on a dry chemistry system, the VetTest 8008 
blood chemistry analyzer (IDEXX Laboratories, West-
brook, ME, USA).
Hepatic lipid peroxidation, nitric oxide and glutathi-
one content
The content of malondialdehyde (MDA), a terminal 
product of lipid peroxidation, was measured by the thiobar-
bituric acid reduction method using a commercially avail-
able kit (Quantichrom TBARS Assay Kit, BioAssay sys-
tems, Hayward, CA, USA). The hepatic GSH levels were 
determined  using  the  improved  DTNB  [5,5′-dithiobis-(2-
nitrobenzoic acid)] method (QuantiChrom GSH Assay Kit; 
BioAssay Systems, Haywad, CA, USA).
Histopathological examination
Liver slices were made from a part of the left lobe and 
fixed immediately in a 10% buffered formalin phosphate so-
lution, embedded in paraffin, and cut into 5 μm sections. 
Four random samples for each liver sample were stained 
with hematoxylin and eosin (H&E) to evaluate the portal 
inflammation, hepatocellular necrosis and Kupffer cell hy-
perplasia. To quantify the degree (%) of hepatic necrosis, 
liver H&E sections were digitally photographed, and the 
percentage of necrotic areas was quantified as the mean of 
10 randomly selected fields within each slide.
Statistical analysis
Results were expressed as means ± standard error 
(SEM). The Kaplan-Meier test was applied to determine 
the significance of the survival rate differences. The sig-
nificance of differences among experimental groups was 
determined using one-way analysis of variance (ANOVA) 
or the corresponding nonparametric (Kruskal-Wallis) test, 
as  required.  Where  significant  effects  were  found,  post 
hoc analysis using the Tukey’s multiple comparison test or 
Mann-Whitney U-test was performed, and p<0.05 was con-
sidered to be statistically significant.Lim, Kim, Park et al. 225
Results
Effect of BC703 on survival rate and serum liver 
enzymes
After intraperitoneal TA injection, the percentage of 
mortality in the positive control group was 66% compared 
with 50, 44 and 44% in mice treated with BC703 at 1, 5 and 
10 mg/kg, respectively. Although mortality was highest in 
the positive control group, there were no significant differ-
ences. Marked increases in the levels of ALT, AST, BUN 
and CRE were shown in TA-treated mice (Table 1). This 
increase was attenuated in mice that received BC703 in a 
dose-dependent manner. Moreover, the group treated with 
10 mg/kg of BC703 showed reduced liver enzyme and renal 
function marker (BUN and CRE) levels to a greater extent 
than the positive control group (p<0.05).
Table 1.  Effect of BC703 on Serum Biochemical Parameters in TA-induced Fulminant Hepatic Failure in Mice
Groups AST (Unit/L) ALT (Unit/L) ALP (Unit/L) BUN (mg/dL) CRE (mg/dL)
Negative control 97.33 ± 21.55* 71.50 ± 8.63* 106.8 ± 9.02* 15.40 ± 1.54* 0.32 ± 0.09*
Positive control (TA alone) 4308.33 ± 246.24 8351.67 ± 890.48 167.50 ± 42.50 72.50 ± 12.50 0.81 ± 0.17
TA+1 mg of BC703/kg 3425.83 ± 722.42 7465.00 ± 700.58 166.25 ± 9.44 57.50 ± 17.50 0.60 ± 0.11
TA+5 mg of BC703/kg 2912.50 ± 435.66* 7275.00 ± 1130.29 150.00 ± 10.80 46.25 ± 10.28* 0.55 ± 0.06*
TA+10 mg of BC703/kg 2301.17 ± 510.10* 6312.50 ± 1351.87* 156.25 ± 11.43 32.50 ± 12.50* 0.45 ± 0.05*
Values are expressed as means ± SEM (in survival animals). The mice in the negative and positive control groups were orally given 
distilled water. The others were orally administered BC703 (1, 5, and 10 mg/kg) for three consecutive days. At 3 h after the last 
oral administration, mice were intraperitoneally injected saline or 200 mg/kg of TA. * Significantly different compared with the 
positive control group (p<0.05)
Fig. 1.  Effect of BC703 on TBARS (A), NO (B), GSH (C) and SOD (D) content in the TA-induced fulminant hepatic 
failure. The mice in the negative and positive control groups were orally given distilled water. The others were 
orally administered with BC703 (1, 5, and 10 mg/kg) for three consecutive days. At 3 h after the last oral admin-
istration, mice were intraperitoneally injected saline or 200 mg/kg of TA. Values are expressed as means ± SEM 
(in survival animals). * Significantly different compared with the positive control group (p<0.05)Protective Effects of BC703 on TA-induced Hepatotoxicity 226
Hepatic levels of GSH, TBARS, NO and SOD
The liver homogenate showed significantly reduced ac-
tivities of GSH and SOD, whereas increased levels of NO 
and TBARS were shown in positive group (Fig. 1). The he-
patic TBARS level in the positive control group was signifi-
cantly increased by 1.9-fold compared with the level in the 
Fig. 2.  The histopathological changes in the liver stained with hematoxyline and eosin in the TA-induced hepatotoxicity (×200). The 
mice in the negative and positive control groups were orally given distilled water. The others were orally administered with 
BC703 (1, 5, and 10 mg/kg) for three consecutive days. At 3 h after the last oral administration, mice were intraperitoneally 
injected saline or 200 mg/kg of TA. In the positive control mice, widespread destruction of the liver architecture was char-
acterized by massive necrosis around the central vein and hemorrhage as well as infiltration of inflammatory cells adjacent 
to necrotic areas. In contrast, the group of mice treated with TA+10 mg/kg of BC703 displayed only a mild scattered spotty 
necrosis and inflammation. (A) Negative control group, (B) positive control group, (C) TA+1 mg/kg of BC703 group, (D) 
TA+5 mg/kg of BC703 group, (E) TA+10 mg/kg of BC703 group.Lim, Kim, Park et al. 227
negative control group after TA injection (p<0.05). BC703 
attenuated the increased TBARS level in BC703 pretreated 
group at 5 and 10 mg/kg (p<0.05). The level of hepatic NO 
was remarkably decreased by BC703 pretreatment in dose-
dependent manners, compared with the positive control 
group. Moreover, the significant decrease in hepatic GSH, 
which was observed in the positive control group as com-
pared with the negative control group, was significantly re-
versed by BC703 pretreatment (p<0.05).
Histopathological observations
The livers of animals in the negative control group 
had normal hepatic cells with well- preserved cytoplasm, 
a prominent nucleus, a nucleolus and visible central veins, 
whereas the liver collected from TA-administered mice 
showed severe hepatic injury characterized by centrilobular 
necrosis, periportal hepatocytic vacoulation and infiltration 
of inflammatory cells (Fig. 2). Most of the parenchyma of 
the liver was destroyed in this group of mice, resulting in 
hepatic failure. Confluent submassive necrosis was noted 
around the central vein in positive control group mice. Also, 
numerous neutrophil infiltrations were seen adjacent to ne-
crotic areas. The lower dose of BC703 (1 mg/kg) did not 
prevent the toxic effect of TA, with large necrotic areas still 
present. The other doses of BC703 (5 and 10 mg/kg) pro-
duced a more or less normal lobular pattern with a mild de-
gree of hepatic injury. Scattered spotty necrosis was found, 
and  some  inflammatory  cells  surrounded  spotty  necrotic 
foci in mice treated with 5 and 10 mg/kg of BC703 (Fig. 
2). The necrotic area was significantly reduced in BC703-
treated mice in a dose-dependent manner compared to the 
positive control group mice (Fig. 2).
Discussion
TA is a centrilobular hepatotoxicant, widely used as 
a model compound to induce acute and chronic liver dis-
eases7,11,12. Liver injury begins with bioactivation of TA to 
TASO and further to TASO2. An unstable and reactive me-
tabolite, TASO2, is thought to initiate necrosis by covalently 
binding to liver macromolecules11,12. Although TA showed 
high specificity for the liver as a target organ, it also pro-
duced a marginal and transient renal injury at excessively 
high doses15. In this study, elevated serum BUN and CRE 
levels were observed in the positive control group, but these 
renal dysfunctions were ameliorated pretreatment of mice 
with BC703. Meanwhile, TA administration caused severe 
acute liver damage in mice, demonstrated by remarkable el-
evation of serum AST and ALT levels in the present study. 
The increased levels of hepatic enzymes in the present study 
are consistent with the findings of several TA- induced liver 
injuries8,11. The increased serum levels of AST and ALT are 
attributed to the damaged structural integrity of the liver. 
Administration of BC703 prevented TA-induced lethality, 
elevation of ALT, AST and lipid peroxidation in a dose- de-
pendent manner. TA is bioactivated by hepatic microsomal 
CYP2E1 to sulfoxide and further to TASO2
10,11. CYP2E1 
metabolizes a large number of low-molecular-weight com-
pounds, many of which are industrial solvents, chemical 
additives, halogenated anesthetics, and drugs16,17. CYP2E1 
activates many xenobiotics to hepatotoxic or carcinogenic 
substances16. An inhibition of CYP2E1 was associated with 
a decrease in toxicity induced by some chemicals, such as 
acetaminophen, benzene, carbon tetrachloride and chloro-
form17,18. In previous studies, a crude saponin extract from 
Platycodon grandiflorum resulted in a significant decrease 
in the CYP2E1-dependent hydroxylation of aniline and 
showed a hepatoprotective effects on CCl4-induced hepatic 
injury in mice5,6. Thus, these results suggest that BC703 
would attenuate the TA-induced hepatic injury in mice by 
suppression of CYP2E1 in the metabolism of TA, and the 
same evidence has been reported by Kang et al.11. In ad-
dition, this assumption was also confirmed by histological 
observation. Perivenous cells contained a higher level of 
CYP2E1 compared to periportal cells, which reflected zonal 
differences in the toxicity of acetaminophen, carbon tetra-
chloride, chloroform and ethanol17,18. In the histopathogical 
examination, perivenous cells were much more severely 
damaged than periportal cells in positive control group 
mice, whereas the pretreatment with BC703 produced only 
a very mild degree of liver injury in a dose-dependent man-
ner.
GSH is the major nonenzymatic antioxidant and regu-
lator of intracellular redox homeostasis and is ubiquitously 
present in all cell types32. In this study, pretreatment with 
BC703 prior to TA-induced hepatic injury inhibited lipid 
peroxidation, and reduces TA-induced hepatic GSH deple-
tion and restored hepatic Cu/Zn SOD activities in the liver. 
A sufficient regenerative response of BC703 by reducing the 
intensity of liver damage could be expected.
In conclusion, BC703 ameliorated hepatic damage and 
improved survival in mice suffering from TA-induced ful-
minant hepatic failure. Although further studies are neces-
sary, BC703 may be a beneficial agent for the management 
of fulminant hepatic failure.
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